Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

Epilepsy Research

Volumn 25, Issue 3, 1996, Pages 217-224

  Sharief, M ^a   Viteri, C ^b   Ben Menachem, E ^c   Weber, M ^d   Reife, R ^e   Pledger, G ^f   Karim, R ^f   Walker, M ^a   Sander, J W A S ^a   Shorvon, S D ^a   Martinez Lage, J ^g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Hospital of Santiago de Compostela   (Spain)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Hopital Saint Julien Nancy   (France)

^e R W Johnson Pharmaceutical Res I   (United States)

^f R W JOHNSON PHARMACEUTICAL RES I   (United States)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

adjunctive therapy; antiepileptic drugs; partial onset seizures; secondarily generalized seizures; topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; EUROPE; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PLACEBOS;

EID: 10544255353     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(96)00029-0     Document Type: Article

References (12)

1. [1] Ben-Menachem, E., Dam, M., Mikkelsen, M., Engelskjøn, H., Henriksen, O., Johannesen, S.I., Schmidt, D., Ried, S. and Proest, G., Topiramate add-on treatment in patients with intractable partial epilepsy: a multicenter study, Epilepsia, 34, Suppl. 2 (1993) 109 (abstract).
2. [2] Brown, S.D., Wolf, H.H., Swinyard, E.A., Twyman, R.E. and White, H.S., The novel anticonvulsant topiramate enhances GABA-mediated chloride flux, Epilepsia, 34, Suppl. 2 (1993) 122-123 (abstract).
3. [3] Conover, W.J. and Iman, R.L., Rank transformations as a bridge between parametric and nonparametric statistics. Am. Statist., 35 (1981) 124-133.
4. [4] Coulter, D.A., Sombati, S. and DeLorenzo, R.J., Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons, Epilepsia, 34, Suppl. 2 (1993) 123 (abstract).
5. [5] Agresti, A., Categorical Data Analysis, Wiley, New York, 1990.
6. [6] Floren, K.L., Graves, N.M., Leppik, I.E., Remmel, R.P., Margul, B.L. and Doose, D.R., Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate, Epilepsia, 30 (1989) 646 (abstract).
7. [7] Lehmann, E.L., Nonparametrics: Statistical Methods for Rates and Proportions, 2nd Edn., Wiley, New York, 1981.
8. [8] Maryanoff, B.E., Nortey, S.O., Gardocki, J.F., Shank, R.P. and Dodgson, S.P., Anticonvulsant O-alkyl sulfamates. 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds, J. Med. Chem., 30 (1987) 880-887.
9. [9] Shank, R.P., Gardocki, J.F., Vaught, J.L., Davis, C.B., Schupsky, J.J., Raffa, R.B., Dodgson, S.J., Nortey, S.O. and Maryanoff, B.E., Topiramate: preclinical evaluation of a structurally novel anticonvulsant, Epilepsia, 35 (1994) 450-460.
10. [10] Sussman, N.M. and Heydorn, W.E., New and investigational antiepilepsy drugs, Exp. Opin. Invest. Drugs, 3 (1994) 355-368.
11. [11] Vaught, J.L., Maryanoff, B.E. and Shank, R.P., The pharmacological profile of topiramate: a structurally novel, clinically effective anticonvulsant, Epilepsia, 32, Suppl. 3 (1991) 19 (abstract).
12. [12] Wilensky, A.J., Ojemann, L.M., Chmelir, T., Margul, B.L. and Doose, D.R., Topiramate pharmacokinetics in epileptic patients receiving carbamazepine, Epilepsia, 30 (1989) 645-646 (abstract).